TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brii Biosciences Limited ( (HK:2137) ) has issued an announcement.
Brii Biosciences Limited reported a decrease in cash reserves and other income for the first half of 2025, primarily due to investments in research and development and operational costs. Despite financial challenges, the company made significant progress in its hepatitis B program with three Phase 2b clinical studies and a strategic partnership for its antibiotic candidate, soralimixin, in Greater China. These developments are expected to enhance the company’s clinical strategy and market positioning in the infectious disease sector.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biotechnology company focused on developing innovative therapies for infectious diseases, particularly aiming for a functional cure for hepatitis B. The company is involved in strategic partnerships to advance its non-core assets and has a strong market focus on delivering transformative therapies for patients with unmet clinical needs.
Average Trading Volume: 6,092,605
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.61B
Learn more about 2137 stock on TipRanks’ Stock Analysis page.